Highlights Agios Pharmaceuticals, Inc.

Equities

AGIO

US00847X1046

Real-time Estimate Cboe BZX Other stock markets 09:58:02 10/05/2024 pm IST			5-day change	1st Jan Change
32.52 ^USD	-1.22%		-5.60%	+46.41%

02/05	Agios Pharmaceuticals Shares Rise After Reporting Smaller Q1 Loss	MT
02/05	Transcript : Agios Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 02, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Agios Pharmaceuticals Shares Rise After Reporting Smaller Q1 Loss	02/05	MT
Earnings Flash (AGIO) AGIOS PHARMACEUTICALS Reports Q1 Revenue $8.2M	02/05	MT
Agios Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05	CI
Agios Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/02	CI
Agios Pharmaceuticals 2023 Loss Widens, Revenue Rises	15/02	MT
Agios Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/02	CI
Agios Pharmaceuticals, Inc. Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio	08/01	CI
Agios' blood disorder drug meets goals of late-stage study	03/01	RE
Agios Pharmaceuticals, Inc. Announces Phase 3 Energize Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia	03/01	CI
Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 2 Portion of the Rise Up Pivotal Study in Sickle Cell Disease at 65Th ASH Annual Meeting and Exposition	10/12	CI
Agios Pharmaceuticals, Inc. Announces Clinical Proof-Of-Concept in Phase 2A Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes	20/11	CI
Agios Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	02/11	CI
Earnings Flash (AGIO) AGIOS PHARMACEUTICALS Posts Q3 Revenue $7.4M, vs. Street Est of $7.5M	02/11	MT
Agios Pharmaceuticals Signs License Deal With Alnylam for Potential Treatment for Rare Blood Disease	03/23/03	MT
Earnings Flash (AGIO) AGIOS PHARMACEUTICALS Reports Q2 Revenue $6.7M, vs. Street Est of $6.46M	03/23/03	MT
Agios Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	03/23/03	CI
Drug developer Servier's brain cancer drug slows tumor progession considerably	04/23/04	RE
Agios Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	04/23/04	CI
Earnings Flash (AGIO) AGIOS PHARMACEUTICALS Posts Q1 Revenue $5.6M	04/23/04	MT
Agios Pharmaceuticals Swings to Q4 Net Income	23/23/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Agios Pharmaceuticals, Inc.

Equities

AGIO

US00847X1046

Highlights

Filters